Renoprotective Effect of Early Inhibition of the Renin-Angiotensin System in Renal Transplant Recipients

• Published in: Transplantation proceedings Vol. 37; no. 2; pp. 991 - 993
• Main Authors: Montanaro, D., Gropuzzo, M., Tulissi, P., Vallone, C., Boscutti, G., Mioni, R., Risaliti, A., Baccarani, U., Adani, G.L., Sainz, M., Bresadola, F., Mioni, G.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01.03.2005; Elsevier Science
• Subjects: Angiotensin II Type 1 Receptor Blockers - pharmacology; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Antihypertensive Agents - therapeutic use; Biological and medical sciences; Blood Pressure - drug effects; Creatinine - metabolism; Enalapril - therapeutic use; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Humans; Hypertension - drug therapy; Kidney Function Tests; Kidney Transplantation - physiology; Losartan - therapeutic use; Medical sciences; Proteinuria; Ramipril - therapeutic use; Renal Artery - ultrastructure; Renin-Angiotensin System - drug effects; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Tetrazoles - therapeutic use; Time Factors; Tissue, organ and graft immunology; Valine - analogs & derivatives; Valine - therapeutic use; Valsartan; Medicine; Renin angiotensin system; Treatment; Urinary system; Surgery; Graft; Early; Inhibitor; Transplantation; Inhibition; Homotransplantation; Kidney
• ISSN: 0041-1345; 1873-2623
• DOI: 10.1016/j.transproceed.2005.01.043

The aim of this work was to study the effect of early administration of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II type-I receptors blockers (ARB) on renal function and proteinuria in renal transplant recipients with good, stable renal function and mild proteinuria. Twenty four patients started ACEI/ARB therapy within 14 months after surgery (RAS−). Before (T0) and every month for 2 years after the initiation of ACEI/ARB we evaluated creatinine clearance (CrCl), proteinuria/day (UP), UP/CrCl (FUP), arterial blood pressure, and serum lipid levels. Twenty-eight patients who never received ACEI/ARB (RAS+) were studied in the same fashion. In the RAS+ CrCl was reduced after 2 years compared with T0 (64.5 ± 2.6 vs 75.0 ± 3.2 mL/min, P < .003); UP and FUP were both significantly increased (666 ± 65 vs 132 ± 20 mg/day 8.8 ± 1.2 vs 2.6 ± 0.6 mg/mL × 10 3; P < .001 and .002) compared with T0. Moreover, UP ( P < .04), FUP ( P < .03), and the percentage reduction of CrCl (11.4% ± 5% vs 4.6% ± 1.8%; P < .05) were greater in RAS+ than RAS− subjects at 2 years of the study. The values of other parameters did not show significant differences between the two groups. In conclusion, this study suggested that ACEI/ARB have renoprotective effects, when used in patients with good stable renal function and mild proteinuria. These drugs may play a role to prevent chronic allograft nephropathy.